News

The US drugmaker said its analysis determined that splitting Pfizer Innovative Health and Pfizer Essential Health would not improve cash flow or better position the businesses competitively. The

The parties hope to complete the deal in Q1 2017.  Pharmaron sees this as a unique opportunity to acquire state-of-the-art Good Manufacturing Practice (GMP) standard facilities for the

The multicenter, randomized Phase 2 trial is evaluating eryaspase as a second-line treatment of patients with metastatic pancreatic cancer. In the study conducted in France, eryaspase was added

The company has submitted a biologics license application (BLA) to the US Food and Drug Administration (FDA) based on the data from the phase 3 Sirround clinical development

The approvals for the new indications, tumor necrosis factor-receptor associated periodic syndrome (TRAPS), hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD) and familial Mediterranean fever (FMF), were based on clinical

SD-809 is an investigational, oral, small-molecule inhibitor of vesicular monoamine 2 transporter, or VMAT2, that is being developed to treat chorea associated with Huntington disease. The positive data

The drug, dubbed Invokamet XR, is a combination of canagliflozin, a sodium glucose cotransporter 2 inhibitor found in Janssen’s Invokana, and an XR formulation of metformin, a commonly

Specifically, Affilogic and Takeda, through its research center in San Diego, California, will leverage their respective competencies to validate and optimize Nanofitins® that enable Takeda to deliver biotherapeutic

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune,